Related by context. All words. (Click for frequent words.) 66 gemcitabine carboplatin 66 hematopoietic cancers 66 relapsed MM 65 postoperative chemotherapy 65 Surgical resection 65 trabectedin 64 Adjuvant chemotherapy 64 Subgroup analysis 64 efavirenz EFV 64 Pertuzumab 64 biliary tract cancer 64 MAGE A3 ASCI 64 KRAS status 64 chemoradiation therapy 64 prostate carcinoma 64 antiangiogenic agents 64 K ras mutations 64 taxane refractory 64 antiangiogenic therapy 63 concurrent chemoradiation 63 adjuvant cisplatin 63 Pemetrexed 63 rituximab Rituxan 63 baseline LDH 63 Neoadjuvant 63 Paraplatin ® 63 Xelox 63 T1a 63 adjuvant radiotherapy 63 cytoreductive nephrectomy 63 pT2 63 liposomal amphotericin B 63 galiximab 63 tiuxetan 63 oral anticoagulation 63 viral kinetics 63 resectable 63 neoadjuvant therapy 62 genotypic resistance 62 NSABP B 62 dasatinib Sprycel 62 XELOX 62 mRCC 62 Cardiotoxicity 62 erlotinib Tarceva 62 anti angiogenic agents 62 malignant ascites 62 pegylated interferon alfa 2b 62 receptor tyrosine kinase inhibitor 62 BENICAR HCT 62 Femara letrozole 62 ritonavir boosted lopinavir 62 STRIDE PD 62 anastrazole 62 relapsed ovarian cancer 62 Dasatinib 62 metaplasia 62 chemotherapy cisplatin 62 HCV SPRINT 62 tigecycline 62 stavudine d4T 62 refractory prostate cancer 62 Hormone Refractory Prostate Cancer 62 sorafenib Nexavar 62 pegylated IFN 62 HGS ETR2 62 radezolid 62 BCIRG 62 APTIVUS R 62 neoadjuvant 62 EndoTAG 62 amisulpride 62 taxane therapy 62 NMIBC 62 glatiramer acetate 62 lymphadenectomy 62 gefitinib Iressa 62 alpha 2a 62 Pegylated Interferon 62 unfractionated heparin UFH 62 chemoradiotherapy 62 fluoropyrimidine 62 gemcitabine cisplatin 62 PEG interferon 62 Bevacizumab Avastin 61 HIV HCV coinfected 61 adjuvant therapies 61 taxotere 61 fulvestrant 61 ixabepilone 61 tumor histology 61 ß blockers 61 bortezomib Velcade 61 adriamycin 61 gemcitabine Gemzar ® 61 PSMA ADC 61 cediranib 61 recurrent glioblastoma multiforme 61 cytoreduction 61 methotrexate therapy 61 castrate resistant 61 Randomized controlled 61 multimodality therapy 61 Helicobacter pylori eradication 61 mycophenolate mofetil 61 thalidomide Thalomid 61 KRAS mutation 61 Natalizumab 61 Doxil ® 61 histologies 61 oral clodronate 61 dexamethasone Decadron 61 Decitabine 61 antiandrogen 61 Velcade bortezomib 61 refractory AML 61 Azacitidine 61 PEG IFN 61 LHRH receptor positive 61 YONDELIS 61 mg/m2 dose 61 Panzem R NCD 61 gadobutrol 61 Cloretazine 61 bevacizumab Avastin 61 Novartis Afinitor 61 mTOR inhibitors 61 paclitaxel carboplatin 61 metastatic malignant melanoma 61 IOP lowering 61 BEACOPP 61 farletuzumab 61 urothelial carcinoma 61 sustained virological response 61 interferon ribavirin 61 surgically resectable 61 pertuzumab 61 metastatic renal cell carcinoma 61 pegylated liposomal doxorubicin 61 lapatinib Tykerb 61 fallopian tube cancers 61 ChronVac C R 61 FOLFOX6 61 stage IIIB 61 mutated K ras 61 trastuzumab Herceptin ® 61 metastatic GIST 61 HCV genotype 61 Interferon alfa 61 Nilotinib 61 antibiotic regimens 61 IV NSCLC 61 neoadjuvant treatment 61 microtubule inhibitor 61 pegylated interferon alfa 61 multicenter randomized controlled 61 Capecitabine 60 efficacy evaluable 60 pimecrolimus cream 60 BEXXAR Therapeutic Regimen 60 docetaxel Taxotere ® 60 Lenalidomide 60 Interferon beta 60 temozolomide TMZ 60 Revlimid lenalidomide 60 complete cytogenetic response 60 HER2 overexpression 60 BARACLUDE ® 60 elevated LDH 60 Elitek 60 idarubicin 60 imatinib Gleevec 60 refractory colorectal cancer 60 HSCT 60 teriflunomide 60 tipranavir 60 Lymph node 60 haematologic 60 pramlintide metreleptin combination 60 5 fluorouracil leucovorin 60 colorectal liver metastases 60 abacavir lamivudine 60 EURIDIS 60 liver metastasis 60 antimetabolite 60 ara C 60 Erlotinib 60 GnRH agonist 60 alefacept 60 FDG PET imaging 60 preoperative chemotherapy 60 Bayer HealthCare Onyx Pharmaceuticals 60 TroVax ® 60 Gemzar gemcitabine 60 taxane chemotherapy 60 Gleevec imatinib 60 paclitaxel Taxol R 60 chemosensitivity 60 moderately emetogenic 60 cisplatin gemcitabine 60 Gemcitabine 60 ECOG PS 60 ribavirin RBV 60 Temsirolimus 60 liposomal doxorubicin 60 SIR Spheres 60 mucinous 60 Lucentis ranibizumab Genentech 60 fluorouracil leucovorin 60 Platinol ® 60 gemcitabine Gemzar 60 metastatic colorectal 60 β blockers 60 biologic DMARD 60 antithrombotics 60 daunorubicin 60 GOUT 60 paclitaxel Taxol ® 60 riociguat 60 APTIVUS 60 cilengitide 60 5-FU/LV 60 lipid lowering agents 60 antitumor effect 60 F FDG PET 60 Copegus ribavirin 60 Neoadjuvant chemotherapy 60 CLL SLL 60 K#N 60 Roche Xeloda 60 CR nPR 60 assessing T DM1 60 adefovir dipivoxil 60 Tipranavir 60 Allovectin 7 ® 60 Hormonal therapy 60 chemotherapeutic regimen 60 null responder 60 peg interferon 60 flutamide 60 follicular lymphomas 60 Aplidin 60 Taxotere ® 60 nonsmall cell lung cancer 60 Aflibercept 60 BRAF V#E mutation 60 trastuzumab DM1 60 surgical debulking 60 interstitial brachytherapy 60 tumor necrosis 60 Adjuvant therapy 60 CIMZIA TM certolizumab pegol 60 hA# 60 oncologic outcomes 60 metastatic bladder 60 inhibitor RG# 60 ACE Inhibitor 60 capecitabine Xeloda 60 tipranavir ritonavir 60 perioperatively 60 antithrombotic agents 60 Fulvestrant 60 mapatumumab 60 interferon alfa 2b 60 phase IIIb 60 metaglidasen 60 metastatic neuroendocrine tumors 60 Anthracycline 60 external beam radiotherapy 60 debulking surgery 60 bicalutamide 60 5alpha reductase 59 busulfan 59 zoledronate 59 suppressive therapy 59 Herceptin trastuzumab 59 metastatic malignant 59 temsirolimus 59 CYT# potent vascular disrupting 59 relapsing remitting MS RRMS 59 fosbretabulin 59 Randomized Phase II 59 autologous SCT 59 demonstrated antitumor activity 59 CHOP chemotherapy 59 weekly subcutaneous injections 59 IRESSA 59 SVR# 59 chemotherapy docetaxel 59 q#h 59 cranial irradiation 59 antibody titer 59 antiretroviral naïve 59 thienopyridine 59 DAPT 59 tumor xenograft models 59 immunomodulatory therapies 59 adjuvant tamoxifen 59 peginterferon alpha 2a 59 elacytarabine 59 Mitomycin C 59 Epirubicin 59 hip resurfacing arthroplasty 59 mitoxantrone plus 59 TNF alpha inhibitor 59 ZACTIMA 59 IFN α 59 Daptomycin 59 salmeterol fluticasone 59 intravenous cyclophosphamide 59 pamidronate 59 interferon α 59 Onrigin 59 Pfizer Camptosar 59 histological subtype 59 ER CHOP 59 doxorubicin cyclophosphamide 59 risk reducing salpingo 59 velafermin 59 Deforolimus 59 Pegasys peginterferon alfa 2a 59 Xanafide 59 seminoma 59 HuMax EGFr 59 recurrent malignant glioma 59 methotrexate monotherapy 59 TURBT 59 Randomised 59 5-fluorouracil/leucovorin 59 alteplase 59 histologic subtype 59 docetaxel Taxotere 59 antiepileptics 59 VELCADE melphalan 59 Stage IIB 59 Bezielle 59 Peginterferon alfa 2b 59 immunosuppressive regimen 59 recombinant interferon 59 T1c 59 peginterferon alfa 59 Vectibix monotherapy 59 Gefitinib 59 hormone receptor status 59 eribulin mesylate 59 idraparinux 59 clodronate 59 samalizumab 59 pCR 59 docetaxel chemotherapy 59 beta blocker therapy 59 boosted protease inhibitor 59 Hurthle cell 59 Teriparatide 59 duplex ultrasonography 59 pretransplant 59 hepatic metastases 59 tacrolimus ointment 59 ZOLINZA 59 Vidaza azacitidine 59 periprocedural MI 59 EndoTAGTM 1 59 Tumor Response 59 lenalidomide Revlimid 59 oral FTY# 59 corticosteroid dexamethasone 59 ORENCIA ® 59 antithymocyte globulin 59 Votrient 59 micafungin 59 trastuzumab Herceptin 59 pain palliation 59 adjuvant radiation 59 nonmetastatic 59 mitomycin 59 differentiated thyroid 59 androgen ablation 59 Faslodex 59 vinca alkaloid 59 Virologic 59 hematological parameters 59 aspirin clopidogrel 59 Hycamtin ® 59 candesartan cilexetil 59 tanespimycin 59 ertapenem 59 unresectable tumors 59 including eniluracil ADH 59 EOquin TM phase 59 calcineurin inhibitors 59 resected pancreatic cancer 59 Mycophenolate Mofetil 59 certolizumab 59 Nesiritide 59 locoregional recurrence 59 PASI scores 59 PegIFN RBV 59 recurrent GBM 59 peritoneal carcinomatosis 59 Proellex TM 59 RhuDex TM 59 conventional angiography 59 refractory ovarian cancer 59 Pegylated Liposomal Doxorubicin 59 agomelatine 59 carboplatin paclitaxel 59 vidofludimus 59 visceral metastases 59 operable breast cancer 59 Secondary efficacy endpoints 59 calcineurin inhibitor 59 adjuvant systemic 59 chemotherapy hormonal therapy 59 treatment naive genotype 59 stage IIIA 59 cinacalcet 59 TAXOTERE R 59 intratympanic 59 Lilly Gemzar 59 oblimersen 59 ovarian suppression 59 ritonavir boosted 59 adjuvant therapy 59 talabostat 59 immunomodulatory agents 59 atazanavir ritonavir 59 antiarrhythmic drug 59 Arimidex anastrozole 59 thyroglobulin 59 hepatocellular carcinomas 59 Cloretazine ® 59 posaconazole 59 androgen deprivation 59 genitourinary cancers 59 metastatic RCC 59 Gliadel Wafer 59 renal tumors 59 corifollitropin alfa 59 Bevacizumab 59 Taxol ® 58 Taxotere chemotherapy 58 tenofovir emtricitabine 58 GIST tumors 58 cART 58 bortezomib Velcade R 58 Aptivus ® 58 dual antiplatelet 58 paclitaxel cisplatin 58 lipid lowering therapies 58 ZD# [001] 58 adenoma recurrence 58 antifolates 58 SCIg 58 low dose cytarabine 58 platinum refractory 58 heavily pretreated patients 58 gastric adenocarcinoma 58 iniparib 58 percutaneous drainage 58 renoprotective 58 tocilizumab 58 postmenopausal osteoporotic women 58 nilotinib Tasigna 58 dose escalation phase 58 APPRAISE 58 EGFR HER2 58 rFVIIa 58 ancrod 58 cyclophosphamide methotrexate 58 rFSH 58 oral Xeloda 58 enzastaurin 58 aromatase inhibitors AIs 58 Dacogen decitabine 58 platelet inhibitor 58 Arranon 58 Oncotype 58 cytotoxic chemotherapy 58 chemopreventive agent 58 ASCUS 58 GW# [003] 58 spiral computed tomography 58 BRIM3 58 nonrandomized 58 Peg IFN 58 EGFR tyrosine kinase inhibitors 58 CTEPH 58 PSA nadir 58 vinorelbine 58 divalproex sodium 58 subgroup analyzes 58 caspofungin 58 abacavir Ziagen 58 paricalcitol 58 recurrent metastatic 58 prostate cancer PCa 58 bendamustine 58 ibandronate 58 Adjuvant Treatment 58 CLARITY study 58 Accelerated Partial Breast Irradiation 58 ACTEMRA TM 58 endocrine therapies 58 epoetin alpha 58 medically inoperable 58 Tarceva TM 58 sipuleucel T 58 decitabine 58 Lapatinib 58 transvaginal sonography 58 imatinib therapy 58 Trastuzumab DM1 58 erlotinib Tarceva ® 58 paclitaxel poliglumex 58 saline placebo 58 photoprotective drug 58 interferon gamma 1b 58 Xeloda ® 58 papillary renal cell carcinoma 58 virologic failure 58 cytotoxic therapy 58 endometrial hyperplasia 58 Posaconazole 58 lymphocytosis 58 therapeutic regimens 58 Nexavar sorafenib 58 pancreatic adenocarcinoma 58 radical nephrectomy 58 epirubicin 58 radioiodine therapy 58 immunosuppressive regimens 58 Adefovir 58 de novo AML 58 Temodar ® 58 Histologic 58 bacillus Calmette Guerin 58 VNP#M 58 antihormonal 58 Peginterferon Alfa 2a 58 Chemoradiation 58 Tesmilifene 58 curative therapy 58 null responder HCV 58 AST ALT 58 refractory NSCLC 58 dalteparin 58 dosage regimens 58 CsA 58 neoadjuvant chemotherapy 58 tipranavir r 58 conventional DMARDs 58 refractory chronic lymphocytic 58 posttransplant 58 ToGA 58 Naive Patients 58 lymph node dissection 58 colorectal carcinoma 58 ABCSG 58 pyrazinamide 58 intra arterial chemotherapy 58 paclitaxel eluting stents 58 TWYNSTA 58 proteasome inhibitor 58 transdermal estradiol 58 tamoxifen Nolvadex ® 58 5FU 58 ELACYT 58 LHRH agonist 58 Gleevec resistant 58 Amrubicin 58 gastrointestinal stromal tumors GIST 58 SERMs 58 antihyperglycemic 58 Bacillus Calmette Guerin BCG 58 herceptin 58 neuroleptic 58 breast carcinoma 58 Degarelix 58 Patients Treated With 58 Betaferon R 58 locoregional 58 ABVD 58 ovarian carcinoma 58 cetuximab Erbitux 58 trials RCTs 58 bladder carcinoma 58 eprotirome 58 MAGE A3 58 prospective multicentre 58 Folfox 58 Fludarabine 58 antiplatelet therapies 58 MGd 58 radiochemotherapy 58 piperacillin tazobactam 58 UPLYSO 58 recurrent NSCLC 58 antianginal 58 nucleoside analog 58 biochemical relapse 58 Sutent sunitinib 58 hepatoma 58 sentinel lymph node biopsy 58 peginterferon 58 NOD SCID mice 58 thyroid carcinoma 58 Clolar ® 58 DMARD 58 somatostatin analogues 58 fludarabine cyclophosphamide 58 Eli Lilly Gemzar 58 protease inhibitor PI 58 epoetin beta 58 oral JAK1 58 MTT assay 58 Roche Herceptin 58 Antitumor Activity 58 goserelin 58 Cytoxan 58 SABCS 58 Certolizumab pegol 58 sunitinib malate 58 gemtuzumab ozogamicin 58 otamixaban 58 Elocalcitol 58 Vitaxin 58 surrogate markers 58 bevacizumab Avastin ® 58 standard chemotherapy regimens 58 DCVax Brain 58 cisplatin resistant 58 IFN beta 58 Ibritumomab Tiuxetan 58 Mitoxantrone 58 Torisel 58 Sorafenib 58 INCB# [003] 58 florbetaben 58 pegylated interferon alpha 57 microtubule targeting 57 FOLFIRI 57 HCV RESPOND 2 57 alkylating agent 57 nab paclitaxel 57 leukemia AML 57 FOLFOX4 57 T#I [002] 57 #F FDG PET 57 pyrimethamine 57 strontium ranelate 57 Castration Resistant Prostate Cancer 57 Prolongs Survival 57 empiric 57 Jevtana 57 bezafibrate 57 Enzastaurin 57 NATRECOR ® 57 APTIVUS r 57 prucalopride 57 adjuvant colon cancer 57 anthracycline chemotherapy 57 CTAP# Capsules 57 BRIM2 57 anti TNFs 57 Stage IIIb 57 Oxaliplatin 57 FDG-PET/CT 57 CBLC# 57 metastatic gastric 57 allogeneic HSCT 57 randomized multicentre 57 immunomodulatory therapy 57 selective modulator 57 Motexafin Gadolinium 57 postoperative mortality 57 HCV Genotype 57 haematological 57 cisplatin chemotherapy 57 Platinol ® cisplatin 57 angiographic outcomes 57 clomipramine 57 Hycamtin 57 pegylated interferons 57 GnRH agonists 57 TACE 57 underwent surgical resection 57 PegIFN 57 insulin glulisine 57 vandetanib 57 blinded randomized controlled 57 efficacy endpoint 57 Follicular Lymphoma 57 CYP#D# genotype 57 completely resected 57 azacitidine 57 Radical prostatectomy 57 q8h 57 genotype 1a 57 urothelial bladder cancer 57 REMINYL ® 57 midstage clinical 57 resectable pancreatic cancer 57 HER2 positive metastatic breast 57 antimicrobial prophylaxis 57 advanced hepatocellular carcinoma 57 oncological outcomes 57 partial remissions 57 Epivir 57 ACCORD Lipid 57 randomized controlled trials RCTs 57 TLK# 57 hematologic abnormalities 57 Prednisone Against Refractory 57 FUSILEV enhances 57 CYP#A# inhibitors 57 indolent lymphomas 57 serum HBV DNA 57 Dabigatran 57 cilostazol 57 Immunosuppression 57 estramustine 57 OvaRex MAb 57 intratumoral 57 Zevalin consolidation 57 fallopian tube carcinoma 57 Sipuleucel T 57 pharmacokinetic interactions 57 macroalbuminuria 57 maximal dose 57 oral Hycamtin 57 CA9 SCAN 57 pharmacodynamic properties 57 Danazol 57 Combination therapy 57 -#.# log# 57 taxane resistant 57 myeloablative 57 ABL1 57 multitargeted 57 neo adjuvant 57 antiplatelet drugs 57 galantamine 57 pelvic lymphadenectomy 57 ISEL 57 Subgroup analyzes 57 stage IIIb 57 Phase Ib II 57 DEB# 57 cabazitaxel 57 FOLPI 57 subanalysis 57 Pegylated interferon 57 Exemestane 57 Targretin capsules 57 Ontak 57 Interferon Alfa 57 everolimus eluting stents 57 Vinorelbine 57 phase Ib 57 Vidofludimus 57 Hepatocellular Carcinoma HCC 57 Sapacitabine 57 plasma pharmacokinetics 57 Papillary 57 pT3 57 microdose 57 uric acid lowering 57 follicular lymphoma FL 57 Photodynamic therapy 57 KRAS mutations 57 Pegylated 57 percutaneous vertebroplasty 57 TASKi3 57 direct thrombin inhibitors 57 Trandolapril 57 TNF alpha antagonist 57 hPAM4 57 standard chemotherapy regimen 57 multicenter Phase II 57 perioperative morbidity 57 TBC# 57 cetuximab Erbitux R 57 TMP SMX 57 Randomized Study 57 FOSRENOL ® 57 dacarbazine chemotherapy 57 AChE inhibitors 57 NCCTG N# 57 oral antidiabetic 57 folinic acid 57 pyridostigmine 57 relapsed SCLC 57 NNRTI resistant virus 57 MYCAMINE 57 voriconazole 57 vinorelbine tartrate 57 Plaquenil 57 prospectively defined 57 antiandrogens 57 Non inferiority 57 clinicopathological features 57 BRAF inhibitor 57 FDA defined valvulopathy 57 Flu Cy 57 RECIST Response Evaluation Criteria 57 dacarbazine 57 Immunotherapeutic 57 bone scintigraphy 57 Alequel 57 immunosuppressive therapies 57 ganetespib 57 curative resection 57 infusional 57 refractory acute myeloid 57 Radioimmunotherapy 57 myelofibrosis polycythemia vera 57 epoprostenol 57 prostate cancer HRPC 57 Yondelis ® 57 prospective nonrandomized 57 hepatorenal syndrome 57 platelet reactivity 57 PrevOnco 57 Gastrointestinal Stromal Tumors 57 MOTIVATE 57 dual endothelin receptor antagonist 57 Phase Ib study 57 Percutaneous Tibial Nerve Stimulation 57 melphalan prednisone 57 refractory multiple myeloma 57 PCa 57 neratinib 57 Estrogen Receptor 57 tamoxifen therapy 57 Tocilizumab 57 fluvastatin 57 Squamous 57 SUTENT ® 57 AZILECT ® 57 resistant hormone refractory 57 trimethoprim sulfamethoxazole 57 refractory myeloma 57 elotuzumab 57 LHRH 57 deferoxamine 57 Erbitux cetuximab 57 vismodegib 57 metastatic HRPC 57 pemetrexed 57 small molecule tyrosine 57 meropenem 57 PROSTVAC TM 57 alvespimycin 57 imatinib Gleevec ® 57 HGPIN 57 clinically evaluable 57 NSTE ACS 57 intravesical therapy 57 adecatumumab 57 Egrifta 57 AVADO 57 pomalidomide 57 preclinically 57 adjuvant chemotherapy 57 Novartis Gleevec 57 thoracoscopic lobectomy 57 prostate cancer CaP 57 DACH platinum 57 evaluating satraplatin 57 etanercept Enbrel 57 Akt inhibitor 57 pharmacodynamic parameters 57 lipid lowering drugs 57 IFN alfa 57 dose atorvastatin 57 Main Outcome Measure 57 neurologic progression 57 CANCIDAS 57 mg/m2 cohort 57 imexon 57 oral ridaforolimus 57 BrachySil TM 57 HER2 positive cancers 57 Campath alemtuzumab 57 COMBIVIR 57 echocardiographic parameters 57 LUX Lung 57 efaproxiral 57 carcinoids 57 delafloxacin 57 metastatic lymph nodes 57 TO AVOID PREGNANCY WHILE 57 Aplidin R 57 dosimetric 57 radiation sensitizer 57 liposomal formulation 57 Oral corticosteroids 57 K ras mutation 56 rHuEPO 56 Parathyroid Hormone 56 cetuximab 56 metastatic renal 56 Randomized Phase 56 Tarceva erlotinib 56 multicentre randomized 56 Androgen deprivation therapy 56 LEXIVA r 56 metastatic kidney 56 sunitinib Sutent 56 Soft Tissue Sarcoma 56 tarenflurbil 56 lenalidomide dexamethasone 56 oxaliplatin Eloxatin 56 NMDA antagonists 56 radiolabeled TM# 56 Cytotoxic 56 pharmacological therapies 56 OnDose 56 Removab 56 flavopiridol 56 valopicitabine 56 stage IIIb IV 56 DHEA supplementation 56 superficial bladder cancer 56 somatostatin analog 56 Gilead Viread 56 endoscopic ultrasonography 56 HBeAg seroconversion 56 Vectibix panitumumab 56 trastuzumab 56 Metastatic breast cancer 56 plus dexamethasone 56 Zarnestra 56 6 mercaptopurine 56 chemo radiotherapy 56 icatibant 56 colorectal cancer liver metastases 56 Zemplar Capsules 56 antiplatelet medications 56 lymph node metastases 56 docetaxel Taxotere R 56 Cardiopulmonary bypass 56 ClearPath HDR 56 complement inhibitor eculizumab 56 cefuroxime 56 TEMODAL 56 dose cohort 56 immunohistochemical 56 chemo immunotherapy 56 CCR5 receptor antagonist 56 iniparib BSI 56 NCCN guidelines 56 somatostatin analogs 56 Pharmacokinetics PK 56 XYOTAX TM 56 mg kg dose 56 Leukemias 56 GV# [001] 56 antiresorptive 56 refractory indolent non 56 RSR# efaproxiral 56 pegfilgrastim 56 Epidermal Growth Factor Receptor 56 Dabigatran etexilate 56 bevacizumab Avastin Genentech 56 specific antigen PSA 56 adalimumab 56 postintervention 56 pan HDAC inhibitor 56 GSK# [001] 56 BR.# 56 endoscopic remission 56 Capesaris 56 heparins 56 Ceflatonin 56 TKI therapy 56 axitinib 56 Cyclophosphamide 56 pharmacologic intervention 56 oral rivaroxaban 56 Nucleoside 56 aldosterone antagonists 56 Tykerb lapatinib 56 antitumor efficacy 56 SLN biopsy 56 d4T stavudine Zerit 56 virotherapy 56 Multiple Ascending Dose 56 epithelial tumors 56 MCyR 56 Mycophenolate mofetil 56 BCG refractory 56 PIX# [002] 56 BYSTOLIC 56 receiving VICTRELIS 56 Fondaparinux 56 Afatinib 56 transurethral resection 56 androgen suppression